In the face of these precedents, our report that Tyrobp deletion promotes tauopathy spread and tau phosphorylation is especially surprising because these biomarkers that are usually associated with disease progression develop in the face of apparent reduction in phenotypic and functional clinical features. This evidence concerns the gene MAPT and tauopathy.